

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b>	<b>Life360, Inc.</b>
<b>ARBN:</b>	<b>629 412 942</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Synge
<b>Date of last notice</b>	27 May 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	8 June 2022 (PDT)
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 1,441,041 Chess Depositary Interests (CDIs)</li> <li>• 16,416 Shares of Common Stock (Shares)(equivalent to 49,248 CDIs)</li> <li>• 193,137 CDIs held by ICCA Labs, LLC<sup>1</sup></li> <li>• 211,720 CDIs held by Stynge Pty Ltd ATF Sandy Bay Trust.</li> <li>• 5,052 Restricted Stock Units (RSUs)</li> <li>• 27,997 Options over Shares (Options)</li> </ul>

<sup>1</sup> James Synge is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to James Synge by reason of his membership interest in ICCA Labs, LLC is 193,137.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Class</b>	Shares & RSUs
<b>Number acquired</b>	471 Shares
<b>Number disposed</b>	471 RSUs (having vested)
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Shares are issued following the vesting and settlement of 471 RSUs which were granted in lieu of the payment of Director and Committee fees <sup>2</sup>
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 1,441,041 CDIs</li> <li>• 16,887 Shares (equivalent to 50,661 CDIs)</li> <li>• 193,137 CDIs held by ICCA Labs, LLC</li> <li>• 211,720 CDIs held by Styngge Pty Ltd ATF Sandy Bay Trust.</li> <li>• 4,581 RSUs</li> <li>• 27,997 Options</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares following the vesting and settlement of RSUs.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

<sup>2</sup> As per Appendix 3Y lodged on 7 May 2021, 1,881 RSUs were granted in lieu of the payment of US\$25,110 of Director and Committee Fees. RSUs vest and are settled quarterly.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.